NYSE · DVA

DaVita Inc.

$235.44 +$1.17 (+0.50%) 1D After hours
Charting by TradingView

Key Metrics

$15.04B
Market cap
19.24×
P/E · TTM
$13.84B
Revenue · TTM
$781.42M
Net income
EPS · TTM $9.61
Dividend yield —
Free cash flow $1.49B
Beta · 1Y 0.06
EBITDA · TTM $2.11B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 6
    The stock moved +23.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6
  • Feb 3
    The stock moved +21.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 3

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$15.04B
Enterprise value$24.96B
Shares outstanding64.2M
52-wk range$101.00 – $239.64
Avg volume · 20D819.7K
Net cash −$9.92B
Book value / share$-9.30
IndustryServices-Misc Health & Allied Services, Nec
ExchangeNYSE
About DaVita Inc.
IPO dateOct 31, 1995
Employees78000

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E19.24
P/S1.09
P/FCF10.07
EV/EBITDA11.82
EV/Sales1.80
Graham №—

Profitability

Gross —
Operating 10.1%
Net 5.6%
FCF 10.8%
ROE / ROIC -246.4% · 11.9%

Financial Health

Current ratio1.42
Quick ratio1.37
Debt / equity-14.07
Debt / EBITDA 5.03
Net cash −$9.92B
Working capital$1.20B

Cash Flow · TTM

Operating CF $2.03B
Capex −$534.62M
Free cash flow $1.49B
Buybacks $994.58M
Dividends paid —
Shareholder yield 6.6%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

1.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings